Patents Assigned to FEDORA PHARMACEUTICALS INC.
  • Publication number: 20230374005
    Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with ?-lactamase inhibitors and/or additional antibiotics (including ?-lactam and non-?-lactam antibiotics) in the treatment or prevention of bacterial infections.
    Type: Application
    Filed: July 25, 2023
    Publication date: November 23, 2023
    Applicant: FEDORA PHARMACEUTICALS INC.
    Inventors: Renata JANKOWSKA, Sameeh M. SALAMA, Samarendra N. MAITI
  • Patent number: 11780832
    Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with ?-lactamase inhibitors and/or other antibiotics (including ?-lactam and non-?-lactam antibiotics) in the treatment or prevention of bacterial infections.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: October 10, 2023
    Assignee: FEDORA PHARMACEUTICALS INC.
    Inventors: Renata Jankowska, Sameeh M. Salama, Samarendra N. Maiti
  • Publication number: 20230149368
    Abstract: Pharmaceutical combinations of LTV-17 (I), a lactivicin derivative, and ?-lactamase inhibitors are provided, wherein the combinations comprise antibacterial agents suitable for use in the treatment or prevention of bacterial infections.
    Type: Application
    Filed: November 10, 2022
    Publication date: May 18, 2023
    Applicant: FEDORA PHARMACEUTICALS INC.
    Inventors: Sameeh M. SALAMA, Samarendra N. MAITI, Renata JANKOWSKA
  • Publication number: 20220324858
    Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with ?-lactamase inhibitors and/or other antibiotics (including ?-lactam and non-?-lactam antibiotics) in the treatment or prevention of bacterial infections.
    Type: Application
    Filed: March 29, 2022
    Publication date: October 13, 2022
    Applicant: FEDORA PHARMACEUTICALS INC.
    Inventors: Renata JANKOWSKA, Sameeh M. SALAMA, Samarendra N. MAITI
  • Patent number: 10759800
    Abstract: The present invention relates to crystalline forms of a diazabicyclooctane derivative represented by Compound I, the process for producing the same and methods for using the same:
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 1, 2020
    Assignees: FEDORA PHARMACEUTICALS INC., MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Michael Kammerer, Frederic Ran
  • Patent number: 10682413
    Abstract: The present invention relates to a pharmaceutical composition and a lyophilisate of a diazabicyclooctane derivative represented by Compound I, a process for producing the same and methods for using the same.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 16, 2020
    Assignees: FEDORA PHARMACEUTICALS INC., MEIJI SEIKA PHARMA CO., LTD.
    Inventor: Kewei Yang
  • Patent number: 10584123
    Abstract: The present invention relates to a process for producing crystalline and amorphous forms of a diazabicyclooctane derivative represented by Compound (I) and methods for producing the same.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: March 10, 2020
    Assignees: FEDORA PHARMACEUTICALS INC., MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Michael Kammerer, Frédéric Ran
  • Patent number: 10544146
    Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1 ,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: January 28, 2020
    Assignee: FEDORA PHARMACEUTICALS INC.
    Inventors: Samarendra N. Maiti, Dai Nguyen, Jehangir Khan, Rong Ling
  • Publication number: 20180305359
    Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1 ,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 25, 2018
    Applicant: FEDORA PHARMACEUTICALS INC.
    Inventors: Samarendra N. MAITI, Dai NGUYEN, Jehangir KHAN, Rong LING
  • Patent number: 10030019
    Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 24, 2018
    Assignee: FEDORA PHARMACEUTICALS INC.
    Inventors: Samarendra N. Maiti, Dai Nguyen, Jehangir Khan, Rong Ling
  • Patent number: 9505761
    Abstract: New bicyclic compounds, their preparation, and their use as antibacterial agents, either alone or in combination with an antibiotic for the treatment of infections caused by ?-lactamase-producing pathogenic bacteria, are described.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: November 29, 2016
    Assignee: FEDORA PHARMACEUTICALS INC.
    Inventors: Samarendra N. Maiti, Dai Nguyen, Jehangir Khan, Rong Ling
  • Publication number: 20160297817
    Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 13, 2016
    Applicant: FEDORA PHARMACEUTICALS INC.
    Inventors: Samarendra N. MAITI, Dai NGUYEN, Jehangir KHAN, Rong LING
  • Patent number: 9393239
    Abstract: A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: July 19, 2016
    Assignee: FEDORA PHARMACEUTICALS INC.
    Inventors: Samarendra N. Maiti, Dai Nguyen, Jehangir Khan, Rong Ling